Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Ian R ReidAnne M HorneBorislav MihovAngela StewartElizabeth GarrattSumwai WongKaty R WiessingMark J BollandSonja BastinGregory D GamblePublished in: The New England journal of medicine (2018)
The risk of nonvertebral or vertebral fragility fractures was significantly lower in women with osteopenia who received zoledronate than in women who received placebo. (Funded by the Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12609000593235 .).
Keyphrases
- clinical trial
- polycystic ovary syndrome
- phase iii
- double blind
- physical activity
- community dwelling
- pregnancy outcomes
- bone mineral density
- randomized controlled trial
- cervical cancer screening
- hip fracture
- adipose tissue
- study protocol
- breast cancer risk
- pregnant women
- skeletal muscle
- metabolic syndrome
- postmenopausal women